Hepatitis C and human immunodeficiency virus coinfections

Journal of Clinical Gastroenterology

Volumn 33, Issue 5, 2001, Pages 367-374

  Dodig, Milan ^a,b   Tavill, Anthony S ^a,b  

^a METROHEALTH MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Coinfection; Hepatitis C virus; Human immunodeficiency virus

Indexed keywords

ABACAVIR; ALPHA INTERFERON; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RIBAVIRIN; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LIVER FAILURE; LIVER TOXICITY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS C; HEPATITIS, TOXIC; HIV INFECTIONS; HUMANS;

EID: 0034750728     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200111000-00005     Document Type: Review

References (97)

1. The prevalence of hepatitis C virus infection in the United States. 1988 trough 1994
2. Prevalence of HIV infection in the United States, 1984-1992
3. Hepatitis C. Prevalence in HIV infected patients: A cross sectional analysis of the US adult clinical trials Group
4. A multicenter study of viral hepatitis in a United States hemophilic population
5. Prevalence of HCV and HGV in patients infected with HIV: Isolation of a new HGV genotype
6. HIV and HCV infection among injecting drug users
7. Hepatitis C virus infection in anti-HIV positive and negative French homosexual men with chronic hepatitis: Comparison of second- and third-generation anti-HCV testing
8. Incidence and determinants of hepatitis C virus infection among individuals at risk for sexually transmitted diseases attending a human immunodeficiency virus type 1 testing program
9. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case. A multicentre study of 423 pairings
10. Lack of mother to infant transmission of hepatitis C virus in human immunodeficiency virus-seronegative women: A prospective study with hepatitis C virus RNA testing
11. Transmission of hepatitis C from mothers to infants
12. Mother to child transmission of hepatitis C virus: Prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1
13. Mother to child transmission of hepatitis C virus: Evidence for preventable peripartum transmission
14. Increased risk of maternal-infant hepatitis C transmission for women coinfected with human immunodeficiency virus type 1
15. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population
16. Hepatitis C virus infection in mothers and infants cohort study
17. Increased transmission of vertical hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV)-infected infants of HIV- and HCV-coinfected woman
18. Perinatal transmission of Hepatitis C Virus from Human immunodeficiency Virus type 1-infected mothers
19. Increased vertical transmission of Human Immunodeficiency Virus from Hepatitis C Virus coinfected mothers
20. National Institutes of Health consensus development conference panel statement: Management of hepatitis C
21. Recommendation for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
22. Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor 8 and 9 concentrates
23. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV
24. Full or partial seroconversion in patients infected by hepatitis C virus
25. Loss of antibodies against hepatitis C in HIV-seropositive intravenous drug users
26. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals
27. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis
28. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort study
29. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs
30. Effect of human immunodeficiency virus on hepatitis C virus infection among injection drug users
31. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort study
32. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
33. Causes and rates of death among methadone maintenance patients before and after the onset of the HIV/AIDS epidemic
34. HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy
35. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C
36. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
37. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C
38. Human immunodeficiency virus infection and hepatitis C pathology
39. Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection
40. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection
41. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
42. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients
43. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men
44. Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients
45. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users
46. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion study
47. Hepatitis C virus infection in patients infected with the human immunodeficiency virus
48. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects
49. Change in transaminases in hepatitis C virus and HIV-coinfected patients after highly active antiretroviral therapy: Differences between complete and partial virologic responders?
50. Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients
51. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV
52. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
53. Rapidly evolving hepatitis C virus-related cirrhosis in human immunodeficiency virus-infected patient receiving triple antiretroviral therapy
54. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients
55. Coinfections of HIV and chronic hepatitis virus
56. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B infection
57. Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine
58. Fulminant hepatic failure in an AIDS patient: Possible zidovudine-induced hepatotoxicity
59. Hepatic morphological alterations induced by zidovudine (ZDV) in an experimental model
60. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy
61. Hepatotoxicity associated with ritonavir
62. Risk factors for heaptotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine
63. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected hemophiliacs
64. Response-adjusted alpha- interferon therapy for chronic hepatitis C in HIV-infected patients
65. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus
66. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV positive patients
67. Ribavirin antagonizes the effect of azidothymidine on HIV replication
68. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: An early report
69. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy
70. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirhotic patients with chronic hepatitis C
71. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data
72. Peginterferon alfa-2a in patients with chronic hepatitis C
73. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis
74. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C
75. Clinical implications of hepatitis C genotype in human immunodeficiency virus infected patients with chronic liver disease
76. Hepatitis C (HCV) genotype and viral titer distribution among Argentinean hepophilic patients in the presence or absence of human immunodeficiency virus (HIV) coinfection
77. Chronic hepatitis C virus infection in haemophilic patients: Clinical significance of viral genotype
78. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA
79. Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia
80. Hepatitis B and hepatitis C prevalence among blood donors and HIV-1 infected patients in Florianopolis-Brazil
81. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users
82. Coinfection with hepatitis viruses and human immunodeficiency virus in multiply transfused patients
83. HBV and HCV infection in i.v. drug addicts: Coinfection with HIV
84. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
85. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease
86. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in randomized, controlled study (CAESAR)
87. Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections
88. Antiviral treatment for human immunodeficiency virus patients co-infected with hepatitis B virus: Combined effect for both infections, an obtainable goal?
89. Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection
90. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
91. Hepatitis B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
92. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
93. Antiviral chemotherapy for the treatment of hepatitis B virus infections
94. Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation
95. The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1 Year follow-up
96. Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men
97. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effect on HIV-1 viral load